Modification and targetting of myeloid cell surface antigens (CD33 and CD123) to enhance the therapeutic index of CAR T-cells for acute myeloid leukaemia

Acute myeloid leukaemia is a blood cancer that affects adults and children, and has very poor therapeutic outcomes, even with the best available treatments including stem cell transplant. CAR T-cells are a novel gene therapy that have revolutionised treatment outcomes in other types of blood cancers. This thesis is dedicated to the development of CAR T-cells for the treatment of acute myeloid leukaemia, with the aim of improving remission rates and increasing the life expectancy of people who are diagnosed with this life-threatening blood cancer.